Sean Ekins 10/26/23 Sean Ekins 10/26/23

Can-Fite To Harness Artificial Intelligence To Develop Novel Anti-Cancer Drugs

Can-Fite signed an agreement with Collaborations Pharmaceuticals, a leading expert in Artificial Intelligence and Machine Learning

Sean Ekins 9/20/23 Sean Ekins 9/20/23

Collaborations Pharmaceuticals And UTMB Awarded A $295,000 Grant For Preclinical Development Of A Nipah Virus Treatment

RALEIGH, NORTH CAROLINA, USA, September 20, 2023/EINPresswire.com/ -- Collaborations Pharmaceuticals, Inc. (CPI) and the Texas Medical Branch (UTMB) are pleased to announce that they were awarded a $295,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), to perform preclinical in vivo studies on a recently identified Nipah virus (NiV) inhibitor.

Sean Ekins 9/5/23 Sean Ekins 9/5/23

PsychoGenics And Collaborations Pharmaceuticals Awarded a $1M Grant To Use AI Platforms To Design New Drugs For Mental Health Disorders

PsychoGenics Inc. (PsychoGenics) and Collaborations Pharmaceuticals, Inc. (CPI) are pleased to announce that they were awarded a $1million Phase I Small Business Innovation Research (SBIR) grant, to use their combined AI tools to design new drugs for mental health disorders.

Sean Ekins 6/15/23 Sean Ekins 6/15/23

Collaborations Pharmaceuticals Announces Publication Of New Enterovirus-D68 And Coxsackie B5 Inhibitor

A new paper published in Antiviral Research describes a new inhibitor of Enterovirus-D68 and Coxsackie B5.

Sean Ekins 5/27/22 Sean Ekins 5/27/22

Collaborations Pharmaceuticals, Inc. Announces Publication On Generative Molecule Design Software MegaSyn

Raleigh –Collaborations Pharmaceuticals, Inc. announces the publication of a paper detailing their generative molecule design software, MegaSyn.